LHCGR: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of LHCGR. The page also collects GeneMedi's different modalities and formats products for LHCGR in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the LHCGR target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes the receptor for both luteinizing hormone and choriogonadotropin. This receptor belongs to the G-protein coupled receptor 1 family, and its activity is mediated by G proteins which activate adenylate cyclase. Mutations in this gene result in disorders of male secondary sexual character development, including familial male precocious puberty, also known as testotoxicosis, hypogonadotropic hypogonadism, Leydig cell adenoma with precocious puberty, and male pseudohermaphtoditism with Leydig cell hypoplasia. [provided by RefSeq, Jul 2008]

Target IDGM-T79473
Target NameLHCGR
Gene ID3973,16867,25477,715999,481365,101088154,281900,100034043
Gene Symbol and SynonymsGpcr19-rs1,HHG,LCGR,LGR2,LH-R,LH/CG-R,LH/CGR,LHCGR,LHR,LHRHR,LSH-R,LSHR,ULG5
Uniprot AccessionP22888,P16235,Q28005
Uniprot Entry NameLSHR_HUMAN,LSHR_RAT,LSHR_BOVIN
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, INN Index
DiseaseCancer
Gene EnsemblENSG00000138039
Target ClassificationGPCR, Tumor-associated antigen (TAA)


Pre-made LHCGR-specific INN-index biosimilar (antibody&conjugates)

Anti-LHCGR therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatDetail
GMP-Bios-INN-778Pre-Made Choriogonadotropin Beta Biosimilar, Recombinant Protein targeting LHCGR: Recombinant therapeutic protein targeting HHG/LCGR/LGR2/LH/CG-R/LH/CGR/LHR/LHRHR/LSH-R/ULG5choriogonadotropin betaLHCGRRecombinant ProteinDetail

Click to check more INN-indexed antibody & protein biosimilar



Pre-made anti-LHCGR inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-LHCGR benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-LHCGR mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Antibody NameSpeciesFormatClassified by tagDetail
Anti-LHCGR monoclonal antibodyHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquinemabFACS/Biofunctional Antibody, Therapeutics Target antibodyDetail



Multi-species LSHR/ LHCGR/ HHG VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine LHCGR VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Products NameSpeciesExpression PlatformDetail
LHCGR VLP (virus-like particle)Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquineMammalian cellProducts Developing






GENEMEDI
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
<